EQANIE Competitors

BrainCo’s leadership draws on deep experience in neuroscience research and expertise in education to deliver entirely new applications of brainwave technology in the education, wellness, and research spaces. We’ve learned important lessons as we’ve grown from a small team in an apartment basement to over 100 employees in 4 offices around the world. Since 2015 we’ve been working on providing the best experience possible for our customers and we’re here to share our progress and innovations with you.

Cognitive health starts here. Neurotrack’s rapid digital cognitive screening can identify patients with cognitive impairment in just 3 minutes. This tool enables clinicians—for the first time ever—to screen and monitor cognitive function as they would any other vital sign. We believe it will increase the number of annual cognitive assessments completed, open the door to meaningful early intervention, improve access to new pharmaceutical treatment options, and validate or alleviate patient concerns. By design, it fits easily within a typical primary care annual wellness visit workflow. It scores instantly and objectively, requires no specialized training to administer, and uses culturally-agnostic symbols and numbers to ensure inclusivity and remove barriers to care. In 40 seconds, a medical assistant can set a patient up to take the screening on a tablet independently in an exam room, then upload results to the EMR. Or patients can be sent a link to take the test remotely and walk in ready to discuss results. As a complement to this first-line screening, Neurotrack offers access to patient education and coaching to support a brain-healthy lifestyle. Neurotrack has published 25 peer-reviewed papers and its solutions have been recognized by leading organizations including the Cleveland Clinic and the National Institute on Aging. Working with providers, health systems and employer partners, Neurotrack has enabled more than 170,000 cognitive assessments on its platform. In February 2023, Neurotrack was named winner of the Alzheimer’s Association Pitch Competition, aimed at identifying innovations to increase cognitive assessment and early detection and diagnosis of dementia within primary care settings. In August 2023, we were named to the Norrsken Impact/100, a list of the world's top impact startups. The company has raised a total of $57 million in funding to support and accelerate its go-to-market push with major health systems and providers.

MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.